- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Researchers Point to IL-26 as Biomarker of Severe COVID-19
High levels of interleukin (IL)-26 levels correlate with an exaggerated inflammatory response that signifies severe cases of the disease, according to researchers.
A study published by researchers in Sweden indicates that systemic interleukin (IL)-26 is a possible biomarker of severe COVID-19.
The findings were published in Frontiers in Immunology.
According to the authors at Sweden’s Karolinska Institutet, high IL-26 levels correlate with an exaggerated inflammatory response that signifies severe cases of the disease.
IL-26 has antiviral and antibacterial effects and mobilizes immune cells to fight bacterial infections in the lungs as well as chronic respiratory disease.
However, the researchers said they conducted the study because the role of IL-26 in COVID-19 has not been thoroughly investigated. There is also a need to know more about these underlying immunological mechanisms in order to find better treatments as well as improved diagnostics.
To conduct the study, researchers recruited 49 patients who had been hospitalized with SARS-CoV-2-infection, 44 of whom had severe symptoms and needed oxygen therapy. The patients were recruited at a hospital in Stockholm from June 2020 to January 2021.
A control group of 27 healthy individuals was also recruited during the same period. The researchers then measured levels of IL-26 protein and other inflammatory compounds in the blood.
The concentration of IL-26 correlates with those of the neutrophil-mobilizing cytokines IL-8 and TNFα, the authors said.
Healthy controls had much lower levels of IL-26.
In addition, "the increase in blood IL-26 correlates with enhanced surface expression of the “don’t eat me” signal CD47 on blood neutrophils isolated from patients with acute COVID-19," the researchers wrote.
In addition, the blood concentration of IL-26 correlates with that of increased lactate dehydrogenase, a marker of tissue damage, and decreased mean corpuscular hemoglobin, which signals hematological abnormalities in COVID-19; both of those are linked with severe disease.
The higher IL-26 levels were also linked with cytokine storm, another signal of severe COVID-19.
The authors said the results are promising but need further study with a larger patient sample.
Reference
Increased IL26 associates with markers of hyperinflammation and tissue damage in patients with acute COVID19. Cardenas EI, Ekstedt S, Piersiala K, et al Front Immunol. Published online November 17, 2022. doi:10.3389/fimmu.2022.1016991
Study Finds ASCT Similarly Safe, Effective in Older and Younger Patients With Multiple Myeloma
November 30th 2023A real-world study suggests high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is feasible for appropriately selected elderly patients, with similar results seen in older and younger patients.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
What We’re Reading: ChatGPT in Health Care; Menthol Ban Meeting; Health System Cyberattack Impact
November 30th 2023ChatGPT is changing health care while also raising questions about artificial intelligence's promises and limitations; 24 Biden officials met with the National Organization of Black Law Enforcement Executives to discuss the FDA’s proposal to ban menthol cigarettes; a recent hospital cyberattack shows how the vulnerability of health care systems can put patients at risk.
Read More
7-Day Dosing of Azacytidine Shows Benefit for Females With High-Risk MDS Not Seen in Males
November 30th 2023Investigators from several medical centers in Japan were surprised to find that women with myelodysplastic syndrome (MDS) had a survival advantage from a 7-day dosing schedule, but that benefit compared with a reduced schedule was not seen in men.
Read More
